onclive· 2mo ago
save<![CDATA[Pembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBC]]>
May 15, 2026read original ↗
<![CDATA[Pembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.]]>
The original article is no longer reachable from this URL.
read full article on onclive ↗🔗 mentioned in this article
no entities indexed yet
comments(0)
5-min edit window · permanent after that